

**CLAIMS:**

- 5 1. A DNA construct comprising a sequence encoding an IgSP-tPA pre-propeptide comprising an immunoglobulin signal peptide fused to a tissue-type plasminogen activator (tPA) propeptide.
2. The DNA construct of claim 1, wherein said immunoglobulin signal peptide is a murine immunoglobulin signal peptide.
3. The DNA construct of claim 2, wherein said murine immunoglobulin signal peptide comprises SEQ ID NO: 3.
- 10 4. The DNA construct of any of claims 1 to 3, wherein said tPA propeptide is a human tPA propeptide, the carboxyl-terminal extremity of said tPA propeptide consisting of amino acids Arg-Xaa-Arg-Arg.
5. The DNA construct of claim 4, wherein said tPA propeptide consists of amino acids 23 to 32 of SEQ ID NO: 2.
- 15 6. The DNA construct of any of claims 1 to 5, wherein said pre-propeptide comprises SEQ ID NO: 1.
7. The DNA construct of any of claims 1 to 6, wherein said DNA construct encodes a fusion polypeptide comprising said IgSP-tPA pre-propeptide fused to a polypeptide of interest.
- 20 8. A DNA construct comprising a sequence encoding a human tissue-type plasminogen activator propeptide (tPA) wherein the carboxyl-terminal extremity of said tPA propeptide consists of amino acids Arg-Xaa-Arg-Arg.
9. The DNA construct of claim 8, wherein said tPA propeptide consists of amino acids 23 to 32 of SEQ ID NO: 2.
- 25 10. The DNA construct of claim 8 or 9, further comprising a signal sequence fused to said tPA propeptide.
11. The DNA construct of any of claims 8 to 10, wherein said DNA construct encodes a fusion polypeptide comprising said tPA propeptide fused to a polypeptide of interest.
- 30 12. The DNA construct of any of claims 1 to 11, wherein said DNA construct is included in a vector.
13. The DNA construct of any of claims 12, wherein said vector is an expression vector.

14. The DNA construct of any of claims 12, wherein said vector is a vector for performing gene activation.
15. A host cell transformed with the DNA construct of any of claims 1 to 14.
- 5 16. The host cell of claim 15, wherein said cell is selected from the group consisting of a CHO cell, a COS cell, a CV1 cell, a mouse L cell, a HT1080 cell, a BHK cell, a HEK293 cell, , a NIH-3T3 cell, a LM cell and a Y1 cell, NS0 and SP2/0 mouse hybridoma and the like, Namalwa, RPMI-8226, Vero, WI-38, MRC-5 and the like.
17. The host cell of claim 16, wherein said cell is a CHO cell.
- 10 18. A process for the production of a polypeptide of interest comprising the step of transfecting a host cell with the DNA construct of any of claims 1 to 14.
19. A process for the production of a polypeptide of interest comprising the step of culturing the host cell of any of claims 15 to 17.
20. The process of claim 18 or 19, further comprising the step of isolating the polypeptide of interest from said host cells.
- 15 21. The process of any of claims 18 to 20, wherein the transfection is stable transfection.
22. Use of the DNA construct of any of claims 1 to 14 for producing a polypeptide of interest.
23. A fusion polypeptide encoded by the DNA constructs of claim 7 or 11.